Indian pharma companies may stand to gain market share due to the potential impact of US tariffs, according to a JPMorgan report.

Micheál Martin said consumers will have to pay more for medicines as threatened US tariffs will lead to high inflation.

Indian pharma companies may stand to gain market share due to the potential impact of US tariffs, according to a JPMorgan ...

Safeguards Of Dapagliflozin's Half Billion USD Sales In China: Astrazeneca. Legal News and Analysis - China - Conventus Law ...

Since taking office in January 2025, the Trump Administration has announced, imposed, or reimposed various tariff-related restrictions on ...

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and ...

The IDEA team will help guide Candel’s commercial strategy development and support the Company’s commercial projects related to CAN-2409. Through this partnership, Candel will gain access to a ...

The rising demand for advanced pharmaceutical intermediates is fueled by technological advancements, such as continuous flow chemistry and automation, enabling increased efficiency and improved ...

The Germany pharmaceutical intermediate market is set for significant expansion ... We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation ...

Welcome to the UroGen Pharma Fourth Quarter and Full Year ... our investigational product for intermediate risk, low grade, non-muscle invasive bladder cancer, ahead of schedule.